Cargando…

CD19xCD3 DART protein mediates human B-cell depletion in vivo in humanized BLT mice

Novel therapeutic strategies are needed for the treatment of hematologic malignancies; and bispecific antibody-derived molecules, such as dual-affinity re-targeting (DART) proteins, are being developed to redirect T cells to kill target cells expressing tumor or viral antigens. Here we present our f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tsai, Perry, Thayer, William O, Liu, Liqin, Silvestri, Guido, Nordstrom, Jeffrey L, Garcia, J Victor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824566/ https://www.ncbi.nlm.nih.gov/pubmed/27119115 http://dx.doi.org/10.1038/mto.2015.24

Ejemplares similares

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Correction: CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
Publicado: (2021)

Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4(+)CD8(+) thymocytes
por: Zou, Wei, et al.
Publicado: (2012)

Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART(®) Molecules
por: Tuyishime, Marina, et al.
Publicado: (2021)

CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Correction to: CD16xCD33 Bispecific Killer Cell Engager (BiKE) as potential immunotherapeutic in pediatric patients with AML and biphenotypic ALL
por: Reusing, Sarah B., et al.
Publicado: (2021)

Detection of HTLV-1 replication and CD4+ proliferation in the humanized BLT mouse model
por: Pise-Masison, Cynthia A, et al.
Publicado: (2015)

Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche
por: Alberti, Gaia, et al.
Publicado: (2023)

Preclinical Evidence of an Allogeneic Dual CD20xCD22 CAR to Target a Broad Spectrum of Patients with B-cell Malignancies
por: Aranda-Orgilles, Beatriz, et al.
Publicado: (2023)

Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
por: Liu, Huicheng, et al.
Publicado: (2021)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model
por: Chauchet, Xavier, et al.
Publicado: (2022)

Rapid evolution of HIV-1 to functional CD8+ T-cell rResponses in humanized BLT mice
por: Dudek, TE, et al.
Publicado: (2012)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436
por: Uckun, Fatih M., et al.
Publicado: (2021)

Two distinct forms of human BLT2: long-form and short-form BLT2
por: Wei, Jun-Dong, et al.
Publicado: (2023)

Selinexor Sensitizes TRAIL-R2-Positive TNBC Cells to the Activity of TRAIL-R2xCD3 Bispecific Antibody
por: Martini, Silvia, et al.
Publicado: (2020)

IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer
por: Lutz, Martina S., et al.
Publicado: (2023)

Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
por: Sloan, Derek D., et al.
Publicado: (2015)

Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and Functions
por: Kaur, Kawaljit, et al.
Publicado: (2022)

The humanized BLT mouse to study HIV transmission
por: Deruaz, M, et al.
Publicado: (2012)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
por: Uckun, Fatih M., et al.
Publicado: (2021)

Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells
por: Wathikthinnakon, Methi, et al.
Publicado: (2022)

Differential Contribution of BLT(1) and BLT(2) to Leukotriene B(4)-Induced Human NK Cell Cytotoxicity and Migration
por: Wang, Meng, et al.
Publicado: (2015)

Hypogammaglobulinemia in BLT Humanized Mice – An Animal Model of Primary Antibody Deficiency
por: Martinez-Torres, Francisco, et al.
Publicado: (2014)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA
por: Watts, Justin, et al.
Publicado: (2022)

The BLT Humanized Mouse Model as a Tool for Studying Human Gamma Delta T Cell-HIV Interactions In Vivo
por: Biradar, Shivkumar, et al.
Publicado: (2022)

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Cocaine-mediated impact on HIV infection in humanized BLT mice
por: Kim, Sohn G., et al.
Publicado: (2015)

Human Breast Milk and Antiretrovirals Dramatically Reduce Oral HIV-1 Transmission in BLT Humanized Mice
por: Wahl, Angela, et al.
Publicado: (2012)

P437: EFFECTIVE IMMUNOTHERAPY OF PEDIATRIC T(8;21) ACUTE MYELOID LEUKEMIA BY REPURPOSING CD3XCD19 TARGETING BISPECIFIC ANTIBODIES
por: Wijnen, Noa, et al.
Publicado: (2023)

Suppression of Gingival NK Cells in Precancerous and Cancerous Stages of Pancreatic Cancer in KC and BLT-Humanized Mice
por: Kaur, Kawaljit, et al.
Publicado: (2017)

P815: HIGH VALENCY OF IGM-2644, A CD38XCD3 IGM BISPECIFIC T CELL ENGAGER, DISPLACES DARATUMUMAB BINDING AND INDUCES POTENT MULTIPLE MYELOMA CELL KILLING
por: Hart, Kevin C., et al.
Publicado: (2023)

Tribody [(HER2)(2)xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells
por: Oberg, Hans H., et al.
Publicado: (2018)

Perspectives on Non-BLT Humanized Mouse Models for Studying HIV Pathogenesis and Therapy
por: Terahara, Kazutaka, et al.
Publicado: (2021)

High-power pseudospark and BLT switches
por: Frank, K, et al.
Publicado: (1988)

High-power pseudospark and BLT switches
por: Frank, K, et al.
Publicado: (1988)

Human Cytomegalovirus Induces Cellular and Humoral Virus-specific Immune Responses in Humanized BLT Mice
por: Crawford, Lindsey B., et al.
Publicado: (2017)

Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal Transmission of HIV-1 in Humanized BLT Mice
por: Denton, Paul W, et al.
Publicado: (2008)

Efficient Inhibition of HIV Replication in the Gastrointestinal and Female Reproductive Tracts of Humanized BLT Mice by EFdA
por: Shanmugasundaram, Uma, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6ljteal1k9d1v7gktqklt7ie4r